Kang Stem Biotech earns patent for rheumatoid arthritis stem cell cure

Published : Jul 20, 2016 - 10:41 Updated : Jul 20, 2016 - 10:41

◀ Back to List
More article by this Writer

[DISCLOSURE] Kang Stem Biotech (217730) announced on July 20 that it has earned patent rights for a pharmaceutical composition comprising stem cells treated with NOD2 agonist for immune disorders and inflammatory diseases such as rheumatoid arthritis.

◀ Back to List
More article by this Writer

LATEST NEWS

>

[Andrei Hagiu] Which products will benefit and which will be disrupted by generative AI
>

Lt. Gen. Ju Il-suk picked as marine corps chief
>

Prosecutors seek 5-year prison term for Samsung chief in merger retrial
>

UN talks on plastic pollution treaty begin with grim outlook
>

Bill proposed to mandate antismoking warnings on e-cigarettes
>

Mercedes-Benz donates W500m for child protection center in Incheon
>

BAT debuts synthetic nicotine e-cigarettes in Korea
>

[More than APT] Changing the value of 'home'
>

[Herald Gallery] Raum der Gedanken
>

Seoul shares jump over 1.3% on tech gains, Trump's pick for treasury post